Background Clinical outcome of heart transplantation in patients with heart failure and ascites has not been reported. Here, the clinical outcome of heart transplantation in patients with heart failure and ascites is evaluated. Between 1989 and 2005, 45 patients with heart failure and ascites underwent an orthotopic heart transplantation. Of the 45 patients, 33 were men (median age 44 years, range 10-63 years). Causes of heart failure included congenital heart disease in 4 patients (9%), dilated cardiomyopathy in 21 patients (47%), rheumatic heart disease in 7 patients (16%), coronary artery disease in 10 patients (22%), and others. Twenty of the 45 patients (44%) had undergone a previous cardiac operation. Hospital mortality occurred in 10 patients (22%) because of bleeding in 4, sepsis with multiple organ failure in 5 and non-diagnostic graft failure in 1 patient. Re-operation for postoperative bleeding occurred in 14 patients (31%). Independent risk factors for hospital death were low serum albumin (odds ratio 0.05; 95% confidence interval 0.003-0.591; p=0.018) and re-operation for bleeding (odds ratio 30.11; 95% confidence interval 2.38-380.26; p=0.009). Conclusions Heart transplantation in patients with heart failure and ascites was associated with high hospital mortality and morbidity. The co-existence of ascites and hypoalbuminemia implied poor prognosis. (Circ J 2007; 71: 1744 -1748 
he continuous improvement in clinical outcome after heart transplantation has established heart transplantation as a standard and efficient therapy for end-stage heart failure. 1 Long-term survival is limited by transplant coronary artery disease and the complications produced by the toxicities of maintenance immunosuppression. [1] [2] [3] In recent decades, survival after heart transplantation is gradually improving, and there is increasing patient risk profiles before transplantation. 4 The increasing patient risk profiles include having had previous cardiac operations, use of mechanical assist devices, diabetes mellitus, critically ill recipients, high pulmonary vascular resistance, prior sensitization, long allograft ischemic time, and use of nonstandard or marginal donors. 4 Both a donor shortage and improved medical treatment of end-stage heart failure will increase the prevalence of patients with severe or late-stage heart failure to heart transplantation. Right ventricular failure and cardiac ascites occur as late complications of endstage heart failure, and its development usually reduces patient survival. [5] [6] [7] Cardiac ascites and cirrhosis might develop in patients with a long history of congestive heart failure and systemic venous hypertension. 8, 9 The clinical outcome of heart transplantation in such patients has not been reported in series. 10 Here, we sought to evaluate the clinical outcome of heart transplantation in patients with end-stage heart failure and cardiac ascites.
Methods

Patients
A total of 241 consecutive patients underwent heart transplantation from June 1989 to July 2005 at National Taiwan University Hospital. Patients with moderate to massive ascites before transplantation were included in the study.
Definitions
The diagnosis of cardiac ascites was based on clinical history, physical examination and abdominal sonography findings. Patients with liver cirrhosis secondary to hepatitis virus infection or alcoholism were excluded from being transplant candidates. The diagnosis of liver cirrhosis was based on ultrasonic findings. [11] [12] [13] The cause of ascites was considered to be cardiac if patients had severe congestive heart failure and no evidence of alcoholic or post-hepatitis liver cirrhosis. None of the patients in the study received a liver biopsy to confirm the diagnosis of liver cirrhosis.
Data on age, gender, diagnosis of heart disease, renal and liver function tests, hemodynamics, allograft ischemic time, and clinical outcome were recorded. Data of the following were derived from cardiac catheterization: right atrial pressure, transpulmonary gradient, and pulmonary vascular resistance. The severity of liver function impairment was graded according to the Child-Pugh score. 14 
Heart Transplantation
All of the procedures of heart transplantation were performed through a median sternotomy. The techniques of cardiopulmonary bypass are described elsewhere. 15 The operative techniques of heart transplantation in patients who have undergone a prior cardiac operation were similar to those in patients receiving transplantation as a first cardiac procedure. In patients who had undergone a previous car-diac operation, a liberal amount of time was allowed for tissue dissection and relief of dense adhesion. Preliminary exposure of femoral vessels was performed in cases with a high risk of severe hemodynamic compromise during resternotomy. Femorofemoral cardiopulmonary bypass can be instituted very rapidly if needed.
Immunosuppression
All patients received triple-drug immunosuppressive therapy according to the heart transplantation protocol described elsewhere. 16, 17 Since 1995, rabbit antithymocyte globulin has been used for induction therapy. Azathioprine (4 mg/kg) was given 1 h before the operation. Solumedrol (1,000 mg) was infused while the aortic cross-clamp was released. Rabbit antithymocyte globulin (1.5-2.5 mg·kg -1 · day -1 ) was given after transplantation for 5 days. Cyclosporine was started orally within 5 days after transplantation or after the recovery of renal function. Cyclosporine dose was adjusted according to renal function and serum cyclosporine level, which was maintained at the trough level of 300-500 ng/ml during the first 3 months after transplantation and then 200-300 ng/ml 1 year after transplantation. Azathioprine was given at 1-2 mg·kg -1 ·day -1 after transplantation, with the dose adjusted to maintain a white blood cell count of 4,000-6,000 /mm 3 . Prednisone (0.5 mg·kg -1 · day -1 ) was started on the second postoperative day and tapered to 0.2 mg·kg -1 ·day -1 by the first month after transplantation. Tacrolimus (FK-506) and mycophenolate mofetil (Cellcept) were used for recurrent rejection or for severe adverse reactions to cyclosporine and azathioprine. Since 2004, mycophenolate mofetil has been used for primary immunosuppression instead of azathioprine. To prevent nephrotoxicity, the cyclosporine dosage was decreased to maintain a serum trough level of 250-350 ng/ml during the first 3 months after transplantation and then 150-250 ng/ml 1 year after transplantation.
All patients were followed monthly at a special cardiac transplantation clinic. Standard chest roentgenogram, blood tests, electrocardiogram and physical examinations were performed routinely at regular intervals.
Statistical Analysis
The results are expressed as the median with a range or as frequencies for the categorical variables. Data analysis was performed using the chi-square test, Fisher's exact test and the Mann -Whitney test. Univariate and multivariate stepwise logistic regression was used to identify independent risk factors for hospital death. The patient and graft survival curve was plotted by the Kaplan -Meier method. Survival was compared by log-rank test between patients with and without ascites. P ≤0.05 was considered statistically significant.
Results
Patient Characteristics
From 1989 to 2005, 241 patients (198 men and 43 women, median age 49 years, range 0-71 years) with endstage heart failure underwent heart transplantation. The causes of heart failure were congenital heart disease in 8 patients (3%), dilated cardiomyopathy in 134 patients (56%), coronary artery disease in 69 patients (29%), and others. Eight patients received a re-transplantation and 4 patients received a combined heart -kidney transplantation. None of the patients had signs of chronic hepatitis virus B or C infection. Chronic alcohol abuse was denied by all patients. Forty-five patients (33 men and 12 women, median age 44 years, range 10-63 years) with end-stage heart failure had moderate to massive ascites before transplantation. The rate of transplant patients with ascites increased slightly from 14% (14/102) during 1989-1998 to 22% (31/139) during 1999-2005. The causes of heart failure were congenital heart disease in 4 patients (9%), dilated cardiomyopathy in 21 patients (47%), rheumatic heart disease in 7 patients (16%), coronary artery disease in 10 patients (22%), and 1 patient each of restrictive cardiomyopathy and transplant coronary artery disease. Patient demographics and laboratory data before transplantation are listed in Table 1 . Twenty of the 45 patients (44%) had undergone a previous cardiac operation, including 2 multiple valve replacements, 1 coronary artery bypass surgery, 1 total cavopulmonary connection, 1 Fontan operation, 1 Rastelli operation, 1 heart transplantation, and 1 Senning operation. The median level of serum total bilirubin was 1.9 mg/dl (range 0.5-9.6 mg/dl), serum albumin 3.4 g/dl (range 1.4-4.8 g/dl), serum blood urea nitrogen 26 mg/dl (range 9.6-109 mg/dl), serum creatinine 1.3 mg/dl (range 0.49-11), serum asparate aminotransferase 34 U/L (range 12-223), and serum alanine aminotransferase 21 U/L (range . Twenty patients (44%) had a prothrombin time prolongation of more than 4 s. The findings of preoperative abdominal sonography showed moderate ascites in 23 patients and massive ascites in 22 patients. Two patients had cardiac cirrhosis before transplantation. The median level of the Child-Pugh score was 9 (range 6-12).
Before transplantation, 13 patients were assessed as being in UNOS status IA, 14 patients in UNOS status IB, and 18 patients in UNOS status II. Before transplantation, 9 patients had endotracheal intubation and mechanical ventilation, 4 patients had an intra-aortic balloon pump, 5 patients had mechanical support with extracorporeal membrane oxygenation, 1 patient had a ventricular assist device, and 4 patients required dialysis treatment because of anuria.
Among the donors, 33 were men and 12 were women (median age 27 years, range 7-66 years). ABO blood types between donors and recipients were identical in 35 cases and compatible in 10 cases. The body weight ratio between donors and recipients ranged from 0.72 to 1.74. The median duration of allograft ischemic time was 160 min (range 40-320 min). All patients underwent an orthotopic heart transplantation. One patient who had transplant coronary artery disease and severe renal impairment underwent combined heart and kidney transplantations.
Clinical Outcomes
For all patients, there were 30 hospital deaths (12%). For 45 transplant patients with cardiac ascites, there were 10 hospital deaths (22%) occurring between 1 and 152 days after transplantation (Table 1) . Patients with cardiac ascites had a higher hospital mortality rate than patients without ascites (22% vs 10%; p=0.042 by Fisher's exact test). The causes of hospital death in patients with cardiac ascites were bleeding in 4 patients, sepsis with multiple organ failure in 5 patients, and non-diagnostic graft failure in 1 patient. Profuse postoperative bleeding requiring re-operation occurred in 14 (31%) of 45 patients with cardiac ascites. Autopsy was performed in 4 of the 10 patients who had died in hospital. Pathological examination of the livers in the 4 patients revealed cardiac cirrhosis with centrilobular necrosis and a varying degree of fibrosis.
Follow up was complete in all patients. The mean duration of follow up was 50.6±43.8 months. For all patients, the 6-month, 1-year, 3-year, 5-year and 10-year patient and graft survival rates were 86.2±2.2%, 81.8±2.5%, 71.0±3.1%, 62.8±3.5% and 44.1±5.3%, respectively. For 45 patients with cardiac ascites, the 6-month, 1-year, 3-year, 5-year and 10-year patient and graft survival rates were 75.4±6.4%, 70.1±7.0%, 70.1±7.0%, 61.6±8.4% and 51.2±9.7%, respectively (Fig 1) . For the 196 patients without ascites, the 6-month, 1-year, 3-year, 5-year and 10-year patient and graft survival rates were 88.7±2.3%, 84.4±2.6%, 71.4±3.5%, 63.2±3.9% and 42.7±6.1%, respectively (Fig 1) . As shown in Fig 1, patients with cardiac ascites had lower 6-month and 1-year patient and graft survival rates than patients without ascites. The survival curves showed no difference beyond 3 years after transplantation.
Among patients with cardiac ascites there were 7 late deaths, the causes of which were sudden death in 3 patients, sepsis with multiple organ failure in 2 patients, non-diagnostic graft failure in 1 patient, and transplant coronary artery disease in 1 patient.
Risks of Hospital Death
As shown in Table 1 , patients who died in hospital had more congenital heart disease, a low recipient and donor body weight, low levels of serum albumin, massive ascites, a low Child-Pugh score, and a high incidence of postoperative re-operation for bleeding. In multivariate logistic regression analysis, the independent risk factors for hospital death were low serum albumin (odds ratio 0.05, 95% confidence interval 0.003-0.591, p=0.018) and re-operation for bleeding (odds ratio 30.11, 95% confidence interval 2.38-380.26, p=0.009).
Discussion
Heart Transplantation
The clinical outcome of heart transplantation is improving. The 30-day survival rate has improved from 84% during the early 1980s to 91% during the late 1990s. 1 The overall 1-year, 5-year and 10-year survival rates for heart transplantation are 80%, 70% and 50%. 1 However, the long-term survival rate remains unchanged despite the ongoing stepwise improvement in early transplant survival. The survival rate for the entire patient cohort of the worldwide registry shows that, after a steep fall in survival during the first 6 months, survival decreases at a linear rate of 3.4% per year. 18 We had a similar result with the hospital survival rate of 88% and the 1-year patient and graft survival rate of 81.8%.
In view of increasing donor shortage, it is imperative to allocate organs to patients with the greatest need and the greatest chance of survival to derive the maximum benefit. 19 But, the quest for reducing the early mortality rate should not be at the expense of needy patients by being over-selective with transplant candidates. 20 The risk factors for early mortality include old donor age; old recipient age; having congenital heart disease or coronary artery disease as the indication for heart transplantation; requiring mechanical circulatory support (temporary or pulsatile ventricular assist device); mechanical ventilation or dialysis at the time of transplant; hospitalized at transplant; prolonged allograft ischemic time; and renal or hepatic dysfunction at the time of transplant. 18 However, the impact of cardiac ascites on the survival of heart transplantation has not been evaluated. In the present study, it was demonstrated that the presence of moderate to massive cardiac ascites at the time of transplant is a significant risk factor for hospital death and early mortality after heart transplantation. The significant reduction of patient and graft survival was sustained until 3 years after transplantation.
Ascites
Cardiac ascites and cirrhosis usually develop in patients who have a long history of congestive heart failure. [5] [6] [7] [8] [9] The occurrence of signs and symptoms of right ventricular failure with ascites and high right atrial pressure is a wellknown poor prognostic sign in patients with end-stage heart failure. In a previous study, patients with a right atrial pressure >12 mmHg had a 47% 1-year survival rate compared with the 68% survival rate for those with a right atrial pressure <12 mmHg. 21 Elevated right atrial pressure resulting from right ventricular failure was also associated with a significantly increased risk of early death after heart transplantation. 22 In addition, liver insufficiency with prolonged prothrombin time or elevated serum levels of liver enzymes before transplantation was an independent predictor of early death after heart transplantation. 23 Prolonged right ventricular failure and systemic venous hypertension will lead to cardiac cirrhosis. Severe bleeding and infection were usually the terminal events. Cardiac cirrhosis was found at autopsy in 75% of the early deaths of heart -lung transplant recipients with right ventricular failure and hyperbilirubinemia. 24 In the present study, 31% of patients with cardiac ascites required a re-operation for profuse postoperative bleeding. Bleeding and sepsis accounted for 9 of 10 hospital deaths in patients with cardiac ascites. Although preoperative abdominal sonography in 43 of 45 patients with cardiac ascites showed no liver cirrhosis, congestive liver fibrosis (cardiac cirrhosis) was confirmed in 4 patients on postmortem pathological examination.
Cardiac cirrhosis is a clinically silent disorder characterized by a spectrum of morphologic alterations in the liver, ranging from mild deposition of sinusoidal collagen to the emergence of broad fibrous septa. 25, 26 Occurrence of cardiac ascites is the hallmark of cardiac cirrhosis. 9 Laboratory tests play only a small role in the diagnosis of cardiac cirrhosis as in the majority of patients with cardiac cirrhosis, serum levels of liver enzymes, bilirubin, and albumin are within the normal range. 9 Ascites is also a manifestation of congestive heart failure and reflects longstanding systemic venous hypertension. The clinical picture of cardiac cirrhosis is usually masked by symptoms and signs of right ventricular failure. A liver needle biopsy may be required to evaluate the presence and severity of cardiac cirrhosis in patients with cardiac ascites.
Hypoalbuminemia
The Child-Pugh score is associated significantly with hepatic decompensation and mortality after cardiac surgery in patients with cirrhosis. Patients with a Child-Pugh score ≥8 have a high mortality rate of 67%. 27 In the present study, the Child-Pugh score was associated with a high hospital mortality rate (Fig 1) .
Preoperative serum albumin was used to quantify nutritional status and underlying disease. An albumin level of <2.5 g/dl was independently associated with an increased risk of re-operation for bleeding, postoperative renal failure, prolonged ventilatory support, intensive care unit stay, and total length of stay after cardiac surgery. 28 Hypoalbuminemia is a powerful risk factor for perioperative complications in patients undergoing cardiac surgery. 29 Dichtl et al reported no perioperative mortality after heart transplantation in patients with cardiac hepatopathy and normal plasma protein levels. 30 In the present study, hypoalbuminemia was the most powerful risk factor for hospital death after heart transplantation. Nine of 25 patients (36%) with cardiac ascites and serum albumin <3.5 g/dl had hospital death, but only 1 of 20 patients (5%) with ascites and serum albumin >3.5 g/dl had hospital death. The co-existence of cardiac ascites and hypoalbuminemia was associated with a poor hospital outcome.
Study Limitations
The present study was limited by its small number of cases and by being a retrospective study. In addition, the duration of right ventricular failure was unknown and the diagnosis of cardiac cirrhosis was not confirmed by liver biopsy. Liver biopsy is associated with a high rate of complications in patients with advanced liver dysfunction. Although the study's results were preliminary, this is the first study of heart transplantation in patients with end-stage heart failure and cardiac ascites. Patients should be carefully selected for heart transplantation, especially those patients with cardiac ascites and serum albumin <3.5 g/dl. Because the hospital mortality rate was not increased in patients with cardiac ascites and normal levels of serum albumin, it is recommended that an invasive liver biopsy or studies of hepatic reserve, such as a liver scintigram and indocyanine green clearance test, may be indicated only in those patients with cardiac ascites and hypoalbuminemia before transplantation.
Conclusions
Heart transplantation in patients with end-stage heart failure and ascites was associated with a high hospital mortality and morbidity. The coexistence of cardiac ascites and hypoalbuminemia implied a poor prognosis.
